DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Clinical trials for DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) trials appear
Sign up with your email to follow new studies for DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for older lymphoma patients: targeted therapy after chemo may wipe out remaining cancer cells
Disease control Recruiting nowThis study is for people aged 70 and older with a type of blood cancer called DLBCL. After standard chemo, some patients still have tiny traces of cancer DNA in their blood. This trial gives those patients an extra treatment called mosunetuzumab to try to clear that DNA and impro…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Danielle Wallace • Aim: Disease control
Last updated May 17, 2026 02:07 UTC
-
Gene-Matched therapy aims to outsmart aggressive lymphoma
Disease control Recruiting nowThis study tests a new approach for people newly diagnosed with a fast-growing blood cancer called diffuse large B-cell lymphoma that has a specific genetic change (TP53 mutation). The treatment is matched to each person's genetic subtype to improve effectiveness. About 35 adults…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated May 17, 2026 02:04 UTC
-
New drug targets Hard-to-Treat blood cancers in early trial
Disease control Recruiting nowThis early-stage study tests a new drug called NX-2127 in adults with certain blood cancers (like CLL or lymphoma) that have returned or not improved after other treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About …
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE1 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 02:03 UTC
-
New hope for aggressive brain lymphoma: 3-drug combo enters phase 2 trial
Disease control Recruiting nowThis study tests a combination of three drugs (pomalidomide, an anti-PD-1 antibody, and selinexor) in people whose primary central nervous system lymphoma has come back or not responded to prior treatment. The goal is to see if this combination can shrink or eliminate tumors. Abo…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Beijing Tongren Hospital • Aim: Disease control
Last updated May 17, 2026 02:03 UTC
-
New hope for elderly lymphoma patients: targeted combo therapy shows promise
Disease control Recruiting nowThis study tests a new drug combination for elderly patients (70+) with a specific type of aggressive lymphoma called double-expressor DLBCL. The treatment includes a targeted drug (chidamide) plus a reduced-intensity chemotherapy, followed by maintenance therapy. The goal is to …
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Ou Bai, MD/PHD • Aim: Disease control
Last updated May 17, 2026 02:02 UTC
-
New drug targets Hard-to-Treat blood cancers in early trial
Disease control Recruiting nowThis study tests an experimental drug called NX-5948 in adults with certain blood cancers (like CLL or lymphoma) that have come back or stopped responding to treatment. The drug works by breaking down a protein that helps cancer cells grow. The main goals are to find a safe dose …
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE1 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 02:01 UTC
-
New combo targets tough lymphoma cases
Disease control Recruiting nowThis study tests a drug called zanubrutinib combined with standard chemotherapy for people newly diagnosed with a fast-growing lymphoma (DLBCL) who have high-risk features. The goal is to see if this combo can improve remission rates and help control the disease better than curre…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Beijing Tongren Hospital • Aim: Disease control
Last updated May 17, 2026 01:59 UTC
-
Double-Targeting CAR t therapy aims to outperform standard treatment in lymphoma
Disease control Recruiting nowThis study tests a new cell therapy called ronde-cel that targets two proteins (CD19 and CD20) on lymphoma cells, compared to standard CAR T-cell therapy that targets only one. About 400 adults with large B-cell lymphoma that came back or didn't respond to first treatment will ta…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE3 • Sponsor: Lyell Immunopharma, Inc. • Aim: Disease control
Last updated May 17, 2026 01:59 UTC
-
Last-Resort cancer drug made available to patients who have no other options
Disease control AVAILABLEThis program provides early access to the investigational drug selinexor for people with multiple myeloma, lymphoma, sarcoma, or other cancers who have exhausted all approved treatments and cannot join a clinical trial. Patients must get approval from their doctor and local healt…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Sponsor: Karyopharm Therapeutics Inc • Aim: Disease control
Last updated May 17, 2026 01:52 UTC
-
New hope for lymphoma patients with hepatitis b: maintenance drug aims to prevent relapse
Disease control Recruiting nowThis study tests whether the drug chidamide can help prevent diffuse large B-cell lymphoma (DLBCL) from coming back in patients who also have hepatitis B and have already responded well to initial chemotherapy (R-CHOP). About 200 adults aged 18–80 will take chidamide as a mainten…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE3 • Sponsor: Ou Bai, MD/PHD • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New hope for elderly lymphoma patients: drug combo targets tough cases
Disease control Recruiting nowThis study tests a combination of three drugs (chidamide, rituximab, and polatuzumab vedotin) in elderly patients with a specific, hard-to-treat form of diffuse large B-cell lymphoma. The goal is to see how many patients achieve complete remission after treatment. About 58 people…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New hope for aggressive blood cancer: experimental drug rocbrutinib faces off against standard care
Disease control Recruiting nowThis study tests a new drug called rocbrutinib against standard treatments for people with a hard-to-treat type of lymphoma (non-GCB DLBCL) that has come back or stopped responding. About 150 adults will be randomly assigned to receive either rocbrutinib alone or a standard chemo…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Guangzhou Lupeng Pharmaceutical Company LTD. • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New CAR-T therapy aims to control Hard-to-Treat blood cancers
Disease control Recruiting nowThis study tests a new treatment called Talikabtagene autoleucel (a CAR-T cell therapy) for adults with B-cell cancers like leukemia or lymphoma that have come back or not responded to standard treatments. The therapy uses a patient's own immune cells, modified to target cancer c…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE2, PHASE3 • Sponsor: Health Institutes of Turkey • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New injection shows promise for Hard-to-Treat lymphoma
Disease control Recruiting nowThis early-stage study tests a new drug called KSV01 in 18 adults with diffuse large B-cell lymphoma that has come back or not responded to prior treatment. The main goal is to check safety and find the right dose. Researchers will monitor side effects and look for signs that the…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE1 • Sponsor: TCRx Therapeutics Co.Ltd • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New cell therapy takes on hard-to-treat brain lymphoma
Disease control Recruiting nowThis study tests a new treatment called Anbal-cel for people with a type of lymphoma in the brain that has returned or not improved with standard therapy. The treatment uses a patient's own immune cells, which are collected, modified, and then given back to attack the cancer. The…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Hyungwoo Cho • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New CAR-T study tracks immune cells in blood cancer fight
Disease control Recruiting nowThis study is for people with certain blood cancers (DLBCL, PMBCL, or ALL) that have not responded to at least two prior treatments. It will track how well the patient's own modified immune cells (CAR-T cells) grow and last in the body after infusion. The goal is to understand ho…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Sponsor: Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia • Aim: Disease control
Last updated May 14, 2026 12:01 UTC
-
New pill hopes to unleash immune system against tough cancers
Disease control Recruiting nowThis early-phase study tests an experimental pill called NX-1607 in adults with advanced cancers that have not responded to standard treatments. The drug aims to boost the body's immune system to fight tumors. The main goals are to check safety and see if the drug can shrink or c…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE1 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
Smart scan strategy aims to customize lymphoma therapy
Disease control Recruiting nowThis study tests a new way to treat diffuse large B-cell lymphoma (DLBCL) by using early PET scans and blood tests (ctDNA) to decide the best treatment plan. About 40 adults with untreated DLBCL will receive standard chemo plus the drug glofitamab, but the number of cycles and ad…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New hope for older lymphoma patients: gentler combo shows promise
Disease control Recruiting nowThis study tests a new treatment for older adults (65 and up) with diffuse large B-cell lymphoma. The treatment combines the standard chemotherapy with three targeted drugs: glofitamab, polatuzumab, and obinutuzumab. The goal is to see if this combination can improve cancer remis…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
Last-Resort hope: new drug offered to lymphoma patients with no options left
Disease control AVAILABLEThis program gives people with certain types of lymphoma (like follicular lymphoma or diffuse large B-cell lymphoma) who have tried all other treatments access to an experimental drug called odronextamab. The goal is to provide a possible treatment option when no others are avail…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 07, 2026 18:39 UTC
-
Last-Resort CAR-T therapy made available for desperate patients
Disease control AVAILABLEThis program provides access to a cancer treatment called tisagenlecleucel (Kymriah) for people with lymphoma, leukemia, or other conditions where standard treatments have failed. It is for patients who cannot join a clinical trial and have no other good options. The goal is to o…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 07, 2026 18:39 UTC
-
New CAR-T therapy aims to control aggressive blood cancer
Disease control Recruiting nowThis study tests a new treatment called TC011, which uses a patient's own immune cells (CAR-T cells) to fight a type of blood cancer called large B-cell lymphoma. The trial is for adults whose cancer has come back or not responded to at least two prior treatments. The goal is to …
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE1, PHASE2 • Sponsor: TICAROS Co., Ltd. • Aim: Disease control
Last updated May 04, 2026 16:31 UTC
-
Can a chinese herbal capsule beat chemo fatigue in lymphoma survivors?
Symptom relief Recruiting nowThis study tests whether Xinlikang capsule can reduce fatigue and improve immune function in people with diffuse large B-cell lymphoma who finished chemotherapy and are in remission. About 80 participants will receive either the capsule or a placebo for several weeks. The goal is…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE2, PHASE3 • Sponsor: Sun Yat-sen University • Aim: Symptom relief
Last updated May 17, 2026 02:04 UTC
-
Lifestyle makeover for lymphoma survivors: a new hope for better living?
Symptom relief Recruiting nowThis study tests whether a personalized healthy lifestyle plan can improve quality of life for people who have survived certain types of lymphoma. It involves 552 adults aged 18-50 who have been in remission for 3 to 10 years. Participants will either receive the lifestyle plan o…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: NA • Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Symptom relief
Last updated May 14, 2026 12:06 UTC
-
Rare lymphoma transformation under microscope in new study
Knowledge-focused Recruiting nowThis study looks at a rare event where an aggressive lymphoma (DLBCL) comes back as a slow-growing (indolent) type. Researchers will review medical records of 50 adults to learn how often this happens, what tests can spot it, and how well different treatments work. The goal is to…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Sponsor: Azienda USL Reggio Emilia - IRCCS • Aim: Knowledge-focused
Last updated May 17, 2026 02:06 UTC
-
Blood cancer registry aims to map Real-World treatment outcomes
Knowledge-focused Recruiting nowThis study is a registry that collects information from about 2,950 adults with certain blood cancers (like CLL, DLBCL, and others) in Germany. Researchers will track what treatments patients receive, how well they work, and how patients feel over time. No new drugs or treatments…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Sponsor: iOMEDICO AG • Aim: Knowledge-focused
Last updated May 17, 2026 02:05 UTC